NCT04245410

Brief Summary

Pancreatic metastases are a rare entity. In cases of metastatic renal carcinoma (RCC) it can present as isolated pancreatic metastasis, considering the possibility of surgical resection. Goals:

  • Define survival after resection of pancreatic cancer metastases renal in a wide range of our country.
  • Identify predictive survival factors Methods: Retrospective multicenter study in which cases of pancreatic resection due to renal cancer metastases.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2019

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

January 25, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

January 28, 2020

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2022

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2022

Completed
Last Updated

November 3, 2020

Status Verified

November 1, 2020

Enrollment Period

3 years

First QC Date

January 25, 2020

Last Update Submit

November 2, 2020

Conditions

Surgical ProcedureDisease Free SurvivalOverall Survival

Keywords

Renal cell carcinomaPancreatic metastasesResection

Outcome Measures

Primary Outcomes (2)

  • Overall survival

    Overall survival (months) from surgical resection of pancreatic metastases

    Up to 60 months

  • Disease free survival

    Disease free survival (months) from surgical resection of pancreatic metastases

    Up to 60 months

Study Arms (1)

Patients surgically treated of pancreatic metastases from RCC

Patients surgically treated of pancreatic metastases from renal cell carcinoma. Pancreaticoduodenectomy, distal pancreatectomy or total pancreatectomy are included.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients operated from renal cell carcinoma in the past that have developed pancreatic metastases. They are included in the study after pancreatic resection.

You may qualify if:

  • Patients with resecable pancreatic metastases from RCC

You may not qualify if:

  • Unresecable pancreatic metastases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gerardo Blanco-Fernández

Badajoz, 06080, Spain

RECRUITING

Related Publications (4)

  • Tosoian JJ, Cameron JL, Allaf ME, Hruban RH, Nahime CB, Pawlik TM, Pierorazio PM, Reddy S, Wolfgang CL. Resection of isolated renal cell carcinoma metastases of the pancreas: outcomes from the Johns Hopkins Hospital. J Gastrointest Surg. 2014 Mar;18(3):542-8. doi: 10.1007/s11605-013-2278-2. Epub 2013 Oct 26.

    PMID: 24163138BACKGROUND

  • Lee SR, Gemenetzis G, Cooper M, Javed AA, Cameron JL, Wolfgang CL, Eckhauser FE, He J, Weiss MJ. Long-Term Outcomes of 98 Surgically Resected Metastatic Tumors in the Pancreas. Ann Surg Oncol. 2017 Mar;24(3):801-807. doi: 10.1245/s10434-016-5619-z. Epub 2016 Oct 21.

    PMID: 27770346BACKGROUND

  • Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, Bracarda S, Basso U, De Giorgi U, Derosa L, Rizzo M, Ortega C, Massari F, Iacovelli R, Milella M, Di Lorenzo G, Buti S, Cerbone L, Burattini L, Montironi R, Santini D, Falconi M, Cascinu S. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol. 2015;22(6):2094-100. doi: 10.1245/s10434-014-4256-7. Epub 2014 Dec 4.

    PMID: 25472645BACKGROUND

  • Chang YH, Liaw CC, Chuang CK. The role of surgery in renal cell carcinoma with pancreatic metastasis. Biomed J. 2015 Mar-Apr;38(2):173-6. doi: 10.4103/2319-4170.137771.

    PMID: 25179721BACKGROUND

MeSH Terms

Conditions

Carcinoma, Renal Cell

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsKidney NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesKidney DiseasesUrologic DiseasesMale Urogenital Diseases

Central Study Contacts

Gerardo Blanco-Fernandez, MD

CONTACT

0034924218022gerardoblanco@unex.es

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of Surgery, Clinical Professor

Study Record Dates

First Submitted

January 25, 2020

First Posted

January 28, 2020

Study Start

March 1, 2019

Primary Completion

March 1, 2022

Study Completion

July 31, 2022

Last Updated

November 3, 2020

Record last verified: 2020-11

Locations

ES(1)